7 Clinics · Kerala & Tamil Nadu · +91 80860 00608 · help@dermavue.com
Overview GLP-1 Injections Belly Fat Ozempic & Wegovy Mounjaro Generic GLP-1 Am I Eligible? PCOS Quiz Titration Tool Diet Plan Exercise Plan
Treatment evidence

Medicine for Fatty Liver in India: What the Evidence Shows

Fatty liver affects roughly a quarter to a third of Indian adults, and for most of them the proven treatment is still weight loss, not a drug. For the first time India now has a medicine approved specifically for the liver, Wegovy (semaglutide 2.4 mg), but only for MASH with moderate-to-advanced scarring (F2 to F3), only non-cirrhotic, and only on top of diet and activity. Most tablets and tonics sold for fatty liver have no evidence. The decision is a physician one, driven by your fibrosis stage.

Reviewed by Dr. Rejeesh Menon, MBBS, MD, FACP, Internal Medicine (TCMC Reg. 40073). Last reviewed 19 October 2026.

Weight loss is the proven foundation, not a pill

Start here, because this is the part that actually works at every stage. In a study of 293 people with biopsy-proven MASH followed for a year, the ones who lost 10% or more of their body weight had about 90% resolution of the steatohepatitis and 45% regression of their fibrosis (Vilar-Gomez 2015). No drug matches that breadth. For simple fatty liver, the common finding where there is fat but little inflammation or scarring, weight loss is the whole treatment and no medicine is indicated at all.

10%+body weight lost
~90%MASH resolution
~45%fibrosis regression

For a Kerala patient this is a rice-and-portions conversation as much as a medicine one. The carbohydrate load of a kanji, parippu and meen curry day is where a lot of the liver fat comes from, and shifting it is the lever most people underuse. Medicine is an add-on for a specific group, never a replacement for this.

The medicines, and what the evidence actually says

One thing to hold onto as you read: the GLP-1 trials enrolled people with MASH and fibrosis, the inflamed, scarring form, not people with mild fatty liver. A bright liver on an ultrasound is not a reason for an injection. The table sorts what has evidence from what does not, and what is approved in India from what is not.

Medicines for fatty liver: evidence and India approval status
OptionWhat the evidence showsIndia statusKey caveat
Weight loss (7 to 10%+) The foundation. Losing 10% or more gave about 90% MASH resolution and 45% fibrosis regression (Vilar-Gomez 2015). First-line for every stage The only thing proven to help simple fatty liver, where no drug is indicated.
Semaglutide 2.4 mg (Wegovy) ESSENCE trial: MASH resolution 62.9% vs 34.3%, and fibrosis improved in 36.8% vs 22.4%, at 72 weeks (NEJM 2025). Approved in India for non-cirrhotic MASH, fibrosis F2 to F3 (CDSCO, July 2026) Not for cirrhosis. Used on top of diet and activity. GI effects, physician decision.
Tirzepatide (Mounjaro) SYNERGY-NASH phase 2: MASH resolution up to 73.3% vs 13.2% placebo (NEJM 2024). Fibrosis figures were not powered to confirm. Available in India for diabetes and weight, not for the liver Investigational for MASH. Phase 3 still running.
Resmetirom (Rezdiffra) The first MASH-specific drug, an oral tablet (FDA March 2024, EU conditional), from MAESTRO-NASH. Not approved and not available in India yet (local trials ongoing) The one patients ask for by name. It is not here yet, so set honest expectations.
Pioglitazone Improves MASH histology, with the strongest signal in people who also have type 2 diabetes. Available in India, used off-label for the liver Weight gain, fluid retention, fracture risk, bladder caution. Not for heart failure.
Vitamin E 800 IU/day About 43% vs 19% histologic improvement in non-diabetic, biopsy-proven NASH (PIVENS, NEJM 2010). Available, but dose and candidacy are a physician decision Non-diabetic MASH only. High-dose safety is debated. Not a supplement-aisle self-start.
Liver tonics, silymarin, UDCA, detox No strong evidence that they change MASLD outcomes. Widely sold Not a substitute for weight loss. Money is better spent on staging and diet.
The line that matters most. The medicine with the real liver evidence is semaglutide itself, and the data that earned it come from the ESSENCE trial. It is available in India as Wegovy, and resmetirom is FDA-approved for the same F2 to F3 group. Good practice follows the international evidence, so a physician treats to the trials, at the dose they used, under proper supervision. What decides your treatment is your fibrosis stage, not which brand happens to carry which label.

Who is a candidate, and who is not

The decision is built on your fibrosis stage, not on how you feel or on the ultrasound grade. We stage it with a FIB-4 fibrosis score first, then a FibroScan to confirm, reading them alongside your liver enzymes and your ultrasound grade.

  • Simple fatty liver, low FIB-4: lifestyle only. No MASH drug is indicated, and this is the majority of fatty livers found on a scan.
  • MASH with F2 to F3 fibrosis, non-cirrhotic: this is the group where medicine, Wegovy in India, enters the conversation, on top of weight loss, as a physician decision.
  • Cirrhosis (F4): no MASH-targeted drug is approved at this stage. Care is specialist hepatology.

Diabetes shifts the balance. It speeds up scarring, which can move the decision toward earlier treatment, and it changes the drug choice: it strengthens the case for pioglitazone and weakens the case for vitamin E, whose evidence is in non-diabetic patients. This is exactly the kind of judgement that belongs with a physician who has your full picture.

What GLP-1 medication costs in India

Pricing is for the GLP-1 medicine itself, at the starting dose, and it is a diagnostic and treatment decision, not a shelf purchase. The branded product that carries the liver data costs more than a diabetes-dose generic; the generic is cheaper but is not approved for the liver indication.

Generic semaglutideFrom ₹325/week
Ozempic (Novo Nordisk)From ₹1,415/week
Mounjaro (Eli Lilly)From ₹3,281/week

For sourcing, brands and how generic semaglutide is priced week to week, see generic semaglutide in India. The exact monthly figure for your dose and format is confirmed at consultation, and medicine home delivery is available across South India.

Safety: when a medicine is the wrong move

  • Signs that scarring has advanced to cirrhosis or decompensation: yellow eyes or skin, a swelling fluid-filled abdomen, confusion or drowsiness, or vomiting blood or black stools. This is urgent hospital care, not a GLP-1 start.
  • Pregnancy, breastfeeding, or planning a pregnancy: GLP-1 medicines are stopped well before conception.
  • A personal or family history of medullary thyroid cancer or MEN2 syndrome: GLP-1 medicines are contraindicated.
  • A history of pancreatitis: GLP-1 medicines need caution, and severe ongoing abdominal pain must be investigated.
  • Pioglitazone specifically: avoid or use with care in heart failure, significant osteoporosis, or bladder cancer concern.
  • Vitamin E specifically: not routine for people with diabetes, and high-dose use is a physician-set, stage-specific decision.

The honest anchor: medicine is not a substitute for weight loss. No approved drug works without the lifestyle foundation underneath it, and for simple fatty liver there is no drug indication at all. If you have signs of advanced liver disease, call 112 or go to a hospital.

Find out whether medicine is even right for you

The useful first step is staging, not a prescription. A physician can read your FIB-4, FibroScan and blood work together and tell you honestly whether you are in the small group a medicine helps, or whether weight loss is your whole treatment. DermaVue runs this as a video consultation across South India, with home blood collection and medicine home delivery.

Book a physician-supervised liver review
Medicine questions

Your questions about fatty liver medicine

No medicine cures fatty liver. The honest picture is better than that word suggests, though. Early fatty liver (simple steatosis) often improves, and can reverse, with 7 to 10% weight loss, no drug needed. The inflammatory form with scarring, called MASH, can also improve and sometimes regress, but it is managed by a physician, not cured by a pill. Once scarring reaches cirrhosis, the goal shifts to managing it, not reversing it.
Yes. In July 2026 CDSCO approved Wegovy (semaglutide 2.4 mg) in India for adults with non-cirrhotic MASH and moderate-to-advanced fibrosis, stages F2 to F3, used alongside a reduced-calorie diet and more activity. It is the first GLP-1 that India has approved for a liver indication. It is not approved for cirrhosis, and it is not meant for mild fatty liver with no significant scarring.
Yes, semaglutide lowers liver fat and improves MASH, and the benefit is strongest at the 2.4 mg dose studied in the ESSENCE trial, which is the Wegovy dose. Ozempic is the same molecule at diabetes doses, so it helps the liver mainly through weight loss and better blood sugar. A good physician treats to the evidence and the dose the trials used, under proper supervision. The word reverse is honest for early fatty liver and early fibrosis; established cirrhosis is managed, not reversed.
There is no medicine chosen by the ultrasound grade alone, because the grade measures fat, not scarring. What matters is your fibrosis stage, worked out from a FIB-4 score and a FibroScan. A grade 2 liver with low fibrosis is treated with weight loss and metabolic care, no drug. A grade 2 liver that turns out to be MASH with F2 to F3 fibrosis is where a medicine like Wegovy enters the conversation, as a physician decision.
Again, it is the fibrosis stage, not the grade, that decides. If staging confirms non-cirrhotic MASH with F2 to F3 fibrosis, Wegovy is the India-approved option, on top of weight loss. If staging shows cirrhosis (F4), no MASH drug is approved for that stage and the care is specialist hepatology. The first step is always to stage properly with a FIB-4 and a FibroScan rather than to guess from the grade.
Not yet. Resmetirom is the first MASH-specific tablet, approved in the US in March 2024 and in Europe, both for non-cirrhotic F2 to F3 MASH. As of October 2026 it is not approved or available in India. An Indian company is running local trials and has signalled an intent to launch, but that is still subject to those trials and CDSCO clearance, so treat it as a future option, not a current one.
There is no approved oral tablet for fatty liver in India, and the common liver tonics, silymarin (milk thistle), UDCA and detox products do not have strong evidence that they change the disease. They are not harmful in the usual sense, but they are not a treatment, and relying on them can delay the things that actually help: weight loss and proper fibrosis staging. Spend the money on a FibroScan and a dietitian instead.
Vitamin E at 800 IU a day has evidence in one specific group: non-diabetic adults with biopsy-proven MASH, where it improved liver histology in about 43% versus 19% on placebo (PIVENS, 2010). It is not recommended routinely for people with diabetes, and it is not for mild fatty liver. High-dose vitamin E has a debated safety record, so the dose and the decision belong with a physician, not the supplement shelf.
GLP-1 medication cost in India runs, at the starting dose, roughly: Generic semaglutide from ₹325/week. Ozempic (Novo Nordisk) from ₹1,415/week. Mounjaro (Eli Lilly) from ₹3,281/week. Branded products that carry the liver data cost more than diabetes-dose generics, and generics, while cheaper, are not approved for the liver indication. The exact monthly figure depends on the drug, the dose and the format, which is why we confirm it at consultation and can arrange medicine home delivery.
No. Every MASH drug trial was run on top of diet and activity, not instead of them, and for simple fatty liver there is no drug indicated at all. Medicine is an add-on for a defined minority with significant scarring, selected by staging. The intervention that helps at every stage, including the early stage where it can genuinely reverse the fat, is sustained weight loss. Think of the medicine as a lever, and the weight loss as the ground you stand on.
Keep going

Next steps

FIB-4 fibrosis calculator

The free blood-score that decides whether a drug is even on the table.

FibroScan CAP and kPa explained

The stiffness number that confirms your fibrosis stage.

Generic semaglutide in India

Sourcing, brands and weekly pricing for the GLP-1 itself.

Ozempic and Wegovy (semaglutide)

The branded semaglutide behind the ESSENCE liver evidence.

Mounjaro (tirzepatide)

The dual-agonist tested for MASH in SYNERGY-NASH.

Fatty Liver (MASLD): the full guide

Diagnosis, staging, and the treatment evidence in one place.
Sources

References

  1. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378. View on PubMed
  2. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025. Published online 30 April 2025. View on PubMed
  3. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med. 2024;391(4):299-310. View on PubMed
  4. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). N Engl J Med. 2010;362(18):1675-1685. View on PubMed
  5. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. View on DOI
  6. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. View on PubMed
  7. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. View on PubMed
  8. Duseja A, Singh SP, De A, et al. Indian National Association for Study of the Liver (INASL) guidelines on management of non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2023. View on PubMed
  9. Central Drugs Standard Control Organisation (CDSCO) approval of semaglutide 2.4 mg (Wegovy) for non-cirrhotic MASH with fibrosis in India, reported July 2026.